{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v.\n\n250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2).","id":"OG000","title":"Biological/Vaccine: Cetuximab"}],"populationDescription":"Trial terminated early. Too few patients to analyze.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Feasibility as Assessed According to Ability to Deliver the Entire Treatment Regimen to 80% of Patients","type":"SECONDARY"}